Sarepta mulls hunt for global partner for DMD drug; Merck pulls cholesterol drug;

Conversations on Twitter :

 @FierceBiotech: J&J's diabetes drug passes FDA panel test despite safety concerns. Story | Follow @FierceBiotech

@RyanMFierce: Another failure for tivantinib $ARQL. Ph2 in colon cancer after PhIII fiasco in lung cancer last year. | Follow @RyanMFierce

> Sarepta ($SRPT) is considering its strategy for finding a global partner for its hot experimental DMD drug, eteplirsen. Article

> KaloBios started a Phase II study for a monoclonal antibody to fight infection in patients with cystic fibrosis. Release

Medical Device News

 @FierceMedDev: Bayer gains FDA nod for long-use IUD. Story | Follow @FierceMedDev

@MarkHFierce: A Swiss Dx company focused on nanotech brought in $3M in new Series A financing. Article | Follow @MarkHFierce

 @DamianFierce: $LLY's jumping back on the companion diagnostics bandwagon with a new Dako partnership. Report | Follow @DamianFierce

> Medtronic hunts for expanded pacer indication with large study. Story

> As of July 1, Malaysia mandates device product registration. Item

Pharma News

@FiercePharma: Stada exec says board would entertain the right offer. Report | Follow @FiercePharma

 @AlisonBFierce: Manufacturers already shipped more than 128M doses of flu vaccine--nearly 95% of the 135M doses made this season. More | Follow @AlisonBFierce

> Merck yanks cholesterol drug Tredaptive from market. News

> Hamburg: FDA has power to require abuse deterrence in painkillers. Item

> Drugmakers run short of Tamiflu, vaccine as flu bug bites hard. Story

And Finally… Merck ($MRK) took the cholesterol pill Tredaptive off shelves after the med failed in big Phase III study. Item


Suggested Articles

Joe Jimenez has (another) new gig. The ex-Novartis boss joined the board of Century Therapeutics, a startup working on off-the-shelf cell therapies.

As Pfizer posts its full-year financials today, as usual it’s also sneaked in several dropped projects from its pipeline.

The short seller thinks Principia’s approach to the treatment of autoimmune diseases is “misguided” and likely to lead to clinical failures.